Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Royalty Pharma plc RPRX

Healthcare Biotechnology
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including... see more

Recent & Breaking News (NDAQ:RPRX)

Smart Money Highlights Oversold Stocks in Small Cap Biotechs

Accesswire January 19, 2016

Repros Announces Court of Appeals' Affirmation of Summary Judgment in Favor of the Company

GlobeNewswire January 11, 2016

Repros Updates Enclomiphene Program

GlobeNewswire January 4, 2016

Repros Updates Proellex® Program

GlobeNewswire December 21, 2015

Repros Therapeutics Receives Complete Response Letter From FDA for Enclomiphene

GlobeNewswire December 1, 2015

Repros Therapeutics Completes Randomization of Phase 2b Study of Vaginal Proellex(R) in Women With Symptomatic Uterine Fibroid Bleeding

GlobeNewswire November 12, 2015

Repros Therapeutics Inc.(R) Reports Third Quarter 2015 Financial Results

GlobeNewswire November 9, 2015

Repros Therapeutics Announces Cancellation of FDA Advisory Committee Meeting to Review Enclomiphene for the Treatment of Secondary Hypogonadism

GlobeNewswire October 29, 2015

Repros Therapeutics Inc.(R) Reports Second Quarter 2015 Financial Results

GlobeNewswire August 10, 2015

Repros Announces Date of FDA Advisory Committee Review of NDA

GlobeNewswire June 8, 2015

Repros Therapeutics Inc.(R) Reports First Quarter 2015 Financial Results

GlobeNewswire May 7, 2015

Repros Announces November 30, 2015 PDUFA Goal Date for New Drug Application

GlobeNewswire April 15, 2015

Repros Receives Confirmation of Eligibility for Submission of a Centralized Marketing Authorization Application to the European Medicines Agency as a New Active Substance

GlobeNewswire April 6, 2015

Repros Announces Acceptance for Filing of NDA

GlobeNewswire April 1, 2015

Repros Therapeutics Inc.(R) Reports Fourth Quarter and Year End 2014 Financial Results

GlobeNewswire March 16, 2015

Repros Submits New Drug Application to FDA for Androxal (R)

GlobeNewswire February 2, 2015

Repros Updates Androxal(R) Global Regulatory Status

GlobeNewswire December 29, 2014

Repros Initiates Two Phase 2B Uterine Fibroid Studies

GlobeNewswire December 29, 2014

Court Rules Inventors Correctly Named on Androxal(R) Patents

GlobeNewswire December 29, 2014

Repros Therapeutics Inc.(R) Reports Third Quarter 2014 Financial Results

GlobeNewswire November 10, 2014